National and Kapodistrian University of Athens
Επίδραση της φαρμακευτικής αγωγής στη λιπώδη νόσο του ήπατος ασθενών με σακχαρώδη διαβήτη τύπου 2, με έμφαση στις νεότερες αντιδιαβητικές θεραπείες
Abstract
dc:descriptionIntroduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of liver disease worldwide. Over time, the therapeutic approach of patients includes a combination of dietary interventions and exercise, aiming at weight loss, with bariatric surgery being the final solution in cases where the initial approach is insufficient. Given the limited available drug options, medical interest has encompassed drugs used for treating the comorbidities of patients with NAFLD. Aim: Aim of the present prospective observational study was to evaluate the effect of Dulaglutide and Empagliflozin on hepatic steatosis, as well as other factors such as body weight, waist circumference, glycemic control, etc. and to compare the results of treatment with these two drugs. Methods: Seventy-eight patients with type 2 Diabetes Mellitus and NAFLD were included in the study, of which 25 belonged to the Empagliflozin group, 25 to the Dulaglutide group and 28 to the control group. Patient evaluation included recording of demographic and anthropometric characteristics, measurement of laboratory parameters and calculation of corresponding scores and indexes related to hepatic steatosis and fibrosis. It also included ultrasonographic and magnetic resonance imaging, at the time of inclusion and at 52 weeks of follow-up, aiming at the assessment of liver stiffness and steatosis. Results: Quantitative assessment of hepatic steatosis by MRI showed that, after one year of treatment, the Empagliflozin group exhibited a statistically significant reduction of liver fat fraction (LFF) from (mean ± SEM) 12.31% ± 1.76% to 9.34% ± 1.39%, (P = 0.007). In contrast, no statistically significant change was observed in the Dulaglutide group and the control group. Additionally, 52% of patients in the Empagliflozin group achieved a relative reduction of LFF of at least 30%. Furthermore, significant reductions in Body Mass Index (BMI) and Fatty Liver Index (FLI) were recorded in all 3 groups, with the Empagliflozin and Dulaglutide groups appearing superior to the control group, as far as weight loss achievement of at least 5% was concerned. Finally, significant positive correlations were observed between changes in LFF and BMI, HbA1c, FLI, aminotransferase levels, AST to Platelet Ratio Index (APRI) and both waist and hip circumference. Conclusions: In the present study, treatment with Empagliflozin appeared to be superior, regarding improvement of hepatic steatosis, compared to the treatment with Dulaglutide, which, despite improving BMI, did not significantly reduce LFF.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koullias, Emmanouil
- Κουλλιάς, Εμμανουήλ
Subjects
dc:subject × 21- Σχετιζόμενη με Μεταβολική δυσλειτουργία Στεατωτική Νόσος του Ήπατος (ΣΜΣΝΗ)
- Τύπου 2 Σακχαρώδης Διαβήτης
- MRI-PDFF
- Ντουλαγλουτίδη
- Εμπαγλιφλοζίνη
- Αγωνιστές υποδοχέα GLP1
- Αναστολείς SGLT-2
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Type 2 diabetes mellitus
- Dulaglutide
- Empagliflozin
- GLP1 receptor agonists
- SGLT-2 inhibitors
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ηπατολογία
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Clinical Medicine
- Medical and Health Sciences
- Hepatology
- Endocrinology, Diabetes and Metabolism
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58443